Charles River Laboratories International, Inc.
- CRL
- NYSE
- Medical - Diagnostics & Research
- Preclinical CRO
- Drug Discovery Services
- Research Models & Services
$300.15
Today −1.99%Quote Oct 16, 2026, 08:00 PM UTC
+6.56%over the last month
Max drawdown −4.1%From 1-month high −3.4%3 months +36.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$14.46B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$308.36
+2.7% from here
Floor
$282.38
5.9% below price
Where the price sits
37 analysts
Analyst range, low to high
$219.00$357.00
- Price $300.15
- Resistance $305.58–$308.65
- Consensus $308.36
The price is right under resistance. Analysts' average target sits about 3% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $1.00B
- Discovery and Safety Assessment$606.5M60.4%
- Research Models and Services$209.5M20.9%
- Manufacturing Support$188.1M18.7%
Industry
Medical - Diagnostics & Research
Employees
19,000
Founded
1947